Search Results - "LeBlanc, Michael L."

Cure Models as a Useful Statistical Tool for Analyzing Survival by OTHUS, Megan, BARLOGIE, Bart, LEBLANC, Michael L, CROWLEY, John J

“…Cure models are a popular topic within statistical literature but are not as widely known in the clinical literature. Many patients with cancer can be…”
Get full text

Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736 by Stephens, Deborah M, Li, Hongli, LeBlanc, Michael L, Puvvada, Soham D, Persky, Daniel, Friedberg, Jonathan W, Smith, Sonali M

“…Utility of combined-modality therapy for patients with limited-stage diffuse large B-cell lymphoma (DLBCL) was shown in the Southwest Oncology Group (SWOG)…”
Get full text

Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001 by Stephens, Deborah M., Li, Hongli, Constine, Louis S., Fitzgerald, Thomas J., Leonard, John P., Kahl, Brad S., Song, Joo Y., LeBlanc, Michael L., Smith, Sonali M., Persky, Daniel O., Friedberg, Jonathan W.

Get full text

Using Cure Models for Trial Analysis and Design by LeBlanc, Michael L.

Get full text

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma by Kamdar, Manali, Li, Hongli, Chen, Robert W., Rimsza, Lisa M., Leblanc, Michael L., Fenske, Timothy S., Shea, Thomas C., Barr, Paul M., Phillips, Tycel J., Leonard, John P., Kahl, Brad S., Friedberg, Jonathan W., Smith, Sonali M.

“…•Five-year follow-up of S1106 demonstrates similar efficacy, MRD negativity, and 5-year survival with RH or RB, but RH was more toxic than RB.•RB showed…”
Get full text

A strategy for full interrogation of prognostic gene expression patterns: exploring the biology of diffuse large B cell lymphoma by Rimsza, Lisa M, Unger, Joseph M, Tome, Margaret E, Leblanc, Michael L

“…Gene expression profiling yields quantitative data on gene expression used to create prognostic models that accurately predict patient outcome in diffuse large…”
Get full text

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001 by Persky, Daniel O, Li, Hongli, Stephens, Deborah M, Park, Steven I, Bartlett, Nancy L, Swinnen, Lode J, Barr, Paul M, Winegarden, 3rd, Jerome D, Constine, Louis S, Fitzgerald, Thomas J, Leonard, John P, Kahl, Brad S, LeBlanc, Michael L, Song, Joo Y, Fisher, Richard I, Rimsza, Lisa M, Smith, Sonali M, Miller, Thomas P, Friedberg, Jonathan W

“…Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in 25% to 30% of patients, with better overall survival (OS) than that for…”
Get full text

Estimating individualized treatment rules by optimizing the adjusted probability of a longer survival by He, Qijia, Zhang, Shixiao, LeBlanc, Michael L, Zhao, Ying-Qi

“…Individualized treatment rules inform tailored treatment decisions based on the patient’s information, where the goal is to optimize clinical benefit for the…”
Get full text

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol by Redman, Mary W, Papadimitrakopoulou, Vassiliki A, Minichiello, Katherine, Hirsch, Fred R, Mack, Philip C, Schwartz, Lawrence H, Vokes, Everett, Ramalingam, Suresh, Leighl, Natasha, Bradley, Jeff, Miao, Jieling, Moon, James, Highleyman, Louise, Miwa, Crystal, LeBlanc, Michael L, Malik, Shakun, Miller, Vincent A, Sigal, Ellen V, Adam, Stacey, Wholley, David, Sigman, Caroline, Smolich, Beverly, Blanke, Charles D, Kelly, Karen, Gandara, David R, Herbst, Roy S

“…The Lung Cancer Master Protocol (Lung-MAP; S1400) is a completed biomarker-driven master protocol designed to address an unmet need for better therapies for…”
Get full text

Exploring interactions in high-dimensional genomic data: an overview of Logic Regression, with applications by Ruczinski, Ingo, Kooperberg, Charles, L. LeBlanc, Michael

“…Logic Regression is an adaptive regression methodology mainly developed to explore high-order interactions in genomic data. Logic Regression is intended for…”
Get full text

Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma by Roberts, Robin A, Sabalos, Constantine M, LeBlanc, Michael L, Martel, Ralph R, Frutiger, Yvette M, Unger, Joseph M, Botros, Ihab W, Rounseville, Matthew P, Seligmann, Bruce E, Miller, Thomas P, Grogan, Thomas M, Rimsza, Lisa M

“…Gene expression profiling (GEP) has identified genes whose expression levels predict patient survival in diffuse large-B-cell lymphoma (DLBCL). Such discovery…”
Get full text

Long-Term Effects of Finasteride on Prostate Cancer Mortality by Goodman, Phyllis J, Tangen, Catherine M, Darke, Amy K, Lucia, M. Scott, Ford, Leslie G, Minasian, Lori M, Parnes, Howard L, LeBlanc, Michael L, Thompson, Ian M

“…The initial report on finasteride for prevention of prostate cancer documented a reduction in prostate cancers but a paradoxical increase in high-grade tumors…”
Get full text

Designing precision medicine trials to yield a greater population impact by Zhao, Ying‐Qi, LeBlanc, Michael L.

“…Traditionally, a clinical trial is conducted comparing treatment to standard care for all patients. However, it could be inefficient given patients’…”
Get full text

Reply to E. Hawkes et al by Persky, Daniel O, Smith, Sonali M, LeBlanc, Michael L, Friedberg, Jonathan W

Get full text

Restricted survival benefit with right‐censored data by Zhang, Shixiao, LeBlanc, Michael L., Zhao, Ying‐Qi

“…The hazard ratio is widely used to quantify treatment effects. However, it may be difficult to interpret for patients and practitioners, especially when the…”
Get full text

Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials by Rutherford, Sarah C, Yin, Jun, Pederson, Levi, Perez Burbano, Gabriela, LaPlant, Betsy, Shadman, Mazyar, Li, Hongli, LeBlanc, Michael L, Kenkre, Vaishalee P, Hong, Fangxin, Blum, Kristie A, Dockter, Travis, Martin, Peter, Jung, Sin-Ho, Grant, Barbara, Rosenbaum, Cara, Ujjani, Chaitra, Barr, Paul M, Unger, Joseph M, Cheson, Bruce D, Bartlett, Nancy L, Kahl, Brad, Friedberg, Jonathan W, Mandrekar, Sumithra J, Leonard, John P

“…Bone marrow biopsies (BMB) are performed before/after therapy to confirm complete response (CR) in patients with lymphoma on clinical trials. We sought to…”
Get full text

Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349) by BLAYNEY, Douglas W, LEBLANC, Michael L, GROGAN, Thomas, GAYNOR, Ellen R, CHAPMAN, Robert A, SPIRIDONIDIS, C. Harris, TAYLOR, Sarah A, BEARMAN, Scott I, MILLER, Thomas P, FISHER, Richard I

“…To test the hypothesis that therapy of intermediate- and high-grade (excluding Burkitt lymphoblastic) lymphoma with cyclophosphamide, doxorubicin, vincristine,…”
Get full text

Quantifying treatment effects using the personalized chance of longer survival by Zhao, Ying‐Qi, Redman, Mary W., LeBlanc, Michael L.

“…The hazard ratio is widely used to measure or to summarize the magnitude of treatment effects, but it is justifiably difficult to interpret in a meaningful way…”
Get full text

Robustifying Trial-Derived Optimal Treatment Rules for A Target Population by Zhao, Ying-Qi, Zeng, Donglin, Tangen, Catherine M, LeBlanc, Michael L

“…Treatment rules based on individual patient characteristics that are easy to interpret and disseminate are important in clinical practice. Properly planned and…”
Get full text

The New NCI Precision Medicine Trials by Harris, Lyndsay N, Blanke, Charles D, Erba, Harry P, Ford, James M, Gray, Robert J, LeBlanc, Michael L, Hu-Lieskovan, Siwen, Litzow, Mark R, Luger, Selina M, Meric-Bernstam, Funda, O'Dwyer, Peter J, Othus, Megan K D, Politi, Katerina, Shepherd, Lois E, Allegra, Carmen J, Chen, Helen X, Ivy, S Percy, Korde, Larissa A, Little, Richard F, McShane, Lisa M, Moscow, Jeffrey A, Patton, David R, Thurin, Magdalena, Yee, Laura M, Doroshow, James H

“…Basket, umbrella, and platform trial designs (master protocols) have emerged over the last decade to study precision medicine approaches in oncology…”
Get full text